Our Science

Our leading competitors have technologies that begin to solve the manufacturing complexity problems.

While focusing exclusively on delivery, our competitors have failed to address the need for better CAR T cells - failing to solve the relapse and safety problems. 

Unlike first-generation platforms, our approach tackles the full challenge: delivery, durability, and disease recurrence

Vector Production

Triple-Engineered Viral Envelope: Novel immune stealth strategy, novel thermostable and serum resistant fusogen, with T cell targeting + memory priming

Producer Cell Line: MAD-7, CRISPR-engineered

CAR Innovation

Computational (AI-assisted) binder design for a suite of CAR T binders across three initial platformed products, plus a clinically validated CD19 CAR

Memory Phenotyping

Triple-Engineering for Persistence: Memory T Differentiation, Metabolic Engineering, and Microenvironment Armoring 

Patient Safety

Triple-Safety Engineering: Drug-controlled CAR expression, drug-controlled kill-switch, and blinded fusogen to eliminate off-target transduction